Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod
FRANKFURT (Reuters) - European regulators on Thursday granted market approval for Merck KGaA and Pfizer's immuno-oncology drug Bavencio to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Health | Merck | Merkel Cell Carcinoma | Pfizer | Skin | Skin Cancer